compound 076

Compound 076 is an experimental chalcone-based small molecule inhibitor currently under investigation for the treatment of ovarian cancer. Identified through advanced 3D-QSAR (Quantitative Structure-Activity Relationship) modeling and validated in vitro against the A2780 ovarian cancer cell line, the compound demonstrates significant antiproliferative activity. Its primary mechanism of action involves the induction of reactive oxygen species (ROS), which triggers oxidative stress and leads to apoptosis in malignant cells. This approach is particularly relevant for addressing chemoresistance, a common challenge in late-stage gynecological cancers. While still in the preclinical stage of development, compound 076 represents a promising lead for the design of more effective and selective chalcone-derived antineoplastic agents.